Unicycive Therapeutics Director Gaurav Aggarwal Resigns Unicycive director Gaurav Aggarwal resigned on Apr 6, 2026 per an SEC 8‑K (Investing.com); governance follow‑up in the next 2–6 weeks will determine impact.

Unicycive Therapeutics Director Gaurav Aggarwal Resigns: Unicycive director Gaurav Aggarwal resigned on Apr 6, 2026 per an SEC 8‑K (Investing.com); governance follow‑up in the next 2–6 weeks will determine impact. 👈 Read full analysis #Unicycive #Biotech #Investing #SmallCapStocks #PharmaNews

Unicycive Therapeutics, Inc. Securities Fraud Class Action Opportunity Investors in Unicycive Therapeutics, Inc. are urged to take action in a significant securities fraud lawsuit. Key details revealed for potential class members.

Unicycive Therapeutics, Inc. Securities Fraud Class Action Opportunity #USA #New_York #Securities_Fraud #Rosen_Law_Firm #Unicycive

Faruqi & Faruqi, LLP Investigates Unicycive Claims for Investor Rights Faruqi & Faruqi, LLP is calling upon investors who faced losses in Unicycive to discuss their legal options and the ongoing class action lawsuit.

Faruqi & Faruqi, LLP Investigates Unicycive Claims for Investor Rights #USA #New_York #Securities_Law #Faruqi_&_Faruqi #Unicycive

Pomerantz Law Firm Files Class Action Against Unicycive Therapeutics Over Securities Violations Pomerantz Law Firm has initiated a class action lawsuit against Unicycive Therapeutics and certain executives alleging securities violations. Investors are invited to participate.

Pomerantz Law Firm Files Class Action Against Unicycive Therapeutics Over Securities Violations #United_States #California #Class_Action #Pomerantz_LLP #Unicycive

Faruqi & Faruqi Investigates Potential Securities Claims for Unicycive Investors Faruqi & Faruqi, LLP is encouraging Unicycive investors who incurred losses to reach out regarding their legal options and to discuss potential claims against the company.

Faruqi & Faruqi Investigates Potential Securities Claims for Unicycive Investors #USA #New_York #Faruqi_&_Faruqi #SEC_Claims #Unicycive

Class Action Lawsuit Filed Against Unicycive Therapeutics by Pomerantz Law Firm Pomerantz LLP has initiated a class action lawsuit against Unicycive Therapeutics, alleging violations over misleading statements and regulatory mishaps. Investors have until October 14, 2025, to join.

Class Action Lawsuit Filed Against Unicycive Therapeutics by Pomerantz Law Firm #United_States #San_Francisco #Pomerantz_LLP #Unicycive #OLC

Faruqi & Faruqi Investigates Unicycive Therapeutics for Investor Claims Faruqi & Faruqi, a prominent securities law firm, is investigating Unicycive Therapeutics for potential legal claims on behalf of affected investors.

Faruqi & Faruqi Investigates Unicycive Therapeutics for Investor Claims #USA #New_York #Securities_Law #Faruqi_&_Faruqi #Unicycive

Pomerantz Law Firm Initiates Class Action Against Unicycive Therapeutics for Securities Violations Pomerantz LLP has filed a class action lawsuit against Unicycive Therapeutics, alleging securities violations and misleading information during the Class Period. Investors may recover damages.

Pomerantz Law Firm Initiates Class Action Against Unicycive Therapeutics for Securities Violations #United_States #California #Class_Action #Pomerantz_LLP #Unicycive

Unicycive Therapeutics Faces Class Action Lawsuit Over Securities Fraud Claims The Schall Law Firm is leading a class action against Unicycive Therapeutics for alleged securities fraud impacting investors. Join now.

Unicycive Therapeutics Faces Class Action Lawsuit Over Securities Fraud Claims #USA #Los_Angeles #Schall_Law_Firm #Securities_Fraud #Unicycive

Faruqi & Faruqi Urges Unicycive Shareholders to Act By October 14, 2025, Regarding Class Action Lawsuit Investors in Unicycive Therapeutics are reminded of the upcoming class action lawsuit. The lead plaintiff deadline is set for October 14, 2025. Act now.

Faruqi & Faruqi Urges Unicycive Shareholders to Act By October 14, 2025, Regarding Class Action Lawsuit #United_States #New_York #ClassAction #Faruqilaw #Unicycive

UNCY Investors Invited to Participate in Class Action Against Unicycive Therapeutics, Inc. Rosen Law Firm is initiating a class action lawsuit for Unicycive Therapeutics, Inc. investors. Join now to claim compensation without fees.

UNCY Investors Invited to Participate in Class Action Against Unicycive Therapeutics, Inc. #USA #New_York #Securities_Fraud #Rosen_Law_Firm #Unicycive

Shareholders of Unicycive Therapeutics Encouraged to Join Class Action Suit Before Deadline Unicycive Therapeutics shareholders are urged to contact The Gross Law Firm to participate in a class action lawsuit. The deadline for registration is October 14, 2025.

Shareholders of Unicycive Therapeutics Encouraged to Join Class Action Suit Before Deadline #United_States #New_York #Class_Action #Gross_Law #Unicycive

Gross Law Firm Alerts Investors of Class Action Lawsuit Against Unicycive Therapeutics Investors in Unicycive Therapeutics, Inc. are being alerted to a class action lawsuit. The lawsuit is focused on misleading statements affecting stock value. Immediate action is required!

Gross Law Firm Alerts Investors of Class Action Lawsuit Against Unicycive Therapeutics #United_States #New_York #Class_Action #Gross_Law_Firm #Unicycive

Unicycive Therapeutics Investors Encouraged to Join Class Action Lawsuit Unicycive Therapeutics investors who suffered losses are urged to contact The Gross Law Firm regarding a class action lawsuit, set to benefit affected shareholders.

Unicycive Therapeutics Investors Encouraged to Join Class Action Lawsuit #United_States #New_York #Class_Action #Gross_Law_Firm #Unicycive

Faruqi & Faruqi, LLP Investigates Unicycive Therapeutics Amid Investor Concerns Faruqi & Faruqi, LLP, a prominent securities law firm, is looking into claims from investors of Unicycive Therapeutics. The firm highlights an urgent deadline approaching for potential lead plaintiffs.

Faruqi & Faruqi, LLP Investigates Unicycive Therapeutics Amid Investor Concerns #USA #New_York #Securities_Class_Action #Faruqi #Unicycive

Unicycive Therapeutics Shareholders Urged to Join Class Action Lawsuit for Recovery Attention Unicycive Therapeutics shareholders: Join the class action lawsuit to recover losses linked to misleading statements and FDA compliance issues.

Unicycive Therapeutics Shareholders Urged to Join Class Action Lawsuit for Recovery #USA #New_York #Class_Action #Gross_Law_Firm #Unicycive

Unicycive Therapeutics Under Legal Fire for Alleged Securities Fraud - Investors Urged to Act Investors in Unicycive Therapeutics, Inc. are being informed of a class action lawsuit concerning securities law violations. Attorneys urge affected parties to act swiftly.

Unicycive Therapeutics Under Legal Fire for Alleged Securities Fraud - Investors Urged to Act #USA #New_York #Levi_&_Korsinsky #SEC_Lawsuit #Unicycive

Investors of Unicycive Therapeutics Receive Legal Attention from Faruqi & Faruqi Law Firm Faruqi & Faruqi, a renowned securities law firm, is investigating possible claims for investors of Unicycive Therapeutics who faced losses exceeding $50,000.

Investors of Unicycive Therapeutics Receive Legal Attention from Faruqi & Faruqi Law Firm #USA #New_York #Securities_Law #Faruqi_&_Faruqi #Unicycive

Pomerantz Law Firm Investigates Unicycive Therapeutics Amid Allegations of Securities Fraud Pomerantz LLP is delving into possible securities fraud at Unicycive Therapeutics, raising concerns for investors following a critical FDA notice.

Pomerantz Law Firm Investigates Unicycive Therapeutics Amid Allegations of Securities Fraud #USA #New_York #Pomerantz_Law #FDA_Response #Unicycive

Unicycive Addresses Manufacturing Issue Ahead of Kidney Drug Decision; Analysts Maintain Buy Rating Unicycive Therapeutics (Nasdaq: UNCY) provided an update on its New Drug Application (NDA) for oxylanthanum carbonate (OLC), its lead candidate for treating hyp

#UNCY updates investors on its NDA for OLC to treat hyperphosphatemia in CKD patients. FDA flagged a third-party vendor issue, but analysts maintain Buy with a $9 PT. June 28 decision still on track.
#unicycive
prismmarketview.com/unicycive-ad...